Skip to main content
SpringerLink
Log in

Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background. To investigate the correlation among some of the commonly used clinical, pathological factors and newer biological indicators, and to identify the independent predictors of distant metastasis at presentation in patients with breast cancer.

Methods. The pathological specimens from 73 patients with breast cancer were retrospectively evaluated by immunohistochemistry. Data on 13 biological indicators; ER, PR, P53, c-erbB-2, PCNA, CEA, Ki-67, Vimentin, Ulex, Nm23, Cathepsin D, Factor VIII, PS2 together with clinical and pathological factors were collected.

Results. A number of highly significant correlations were found among the biological indicators studied. By logistic regression analysis, the predictors of distant metastasis at presentation in univariate tests were tumor diameter, number of lymph nodes involved, P53, c-erbB-2 and grade. In multivariate analysis, tumor diameter (P=0.042, HR: 1.88(1.02–3.44)), c-erbB-2 expression (P=0.035, HR: 18.20 (1.23–268.66)) and grade (P=0.010, HR: 8.05(1.66–39.00)) retained their significance.

Conclusion. Our findings show that inactivation of suppressor genes, expression of oncogenes, loss of differentiation, augmentation of proliferative activity, metastatic potential, angiogenesis and hormone receptor status are all interrelated facets of breast cancer pathogenesis. Patients with tumors overexpressing c-erbB-2 or with bigger or higher-grade tumors probably need to be more carefully evaluated for the presence of distant metastasis, thus be better staged, at presentation. This may be a new reason to test c-erbB-2 routinely in all patients with breast cancer in addition to its well-known prognostic and predictive uses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gusterson B, Machin L, Gullick W, Gibbs NM, Powles TJ, Price P, McKinna A, Harrison S: Immunohistochemical distribution of c-erbB2 in infiltrating and in situ breast cancer. Int J Cancer 842-845, 1988

  2. Berns EM, Foekens JA, Van Stavaren IL, Van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995

    Google Scholar 

  3. Hayes DF, Yamauchi H, Stearns V, Brotzman M, Isaacs C, Trock B: Should all breast cancers be tested for c-erb-B2? In: Perry MC (ed) ASCO 2000 Educational Book. Baltimore, American Society of Clinical Oncology, 2000, pp 257-265

    Google Scholar 

  4. Savas B, Karaveli S, Uslu G, Basaran L: Significance of P53 and c-erbB-2 for predicting response to CMF treatment in breast carcinoma. Proc ASCO 18: 378 (abstr), 1999

    Google Scholar 

  5. Culotta E, Koshland D: Molecules of the year: P53 sweeps through cancer research. Science 262: 1958-1961, 1993

    Google Scholar 

  6. Sauer T, Furu I, Beraki K, Jebsen PW, Ormerod E, Naess O. Nm 23 protein expression in fine-needle aspirates from breast carcinoma. Cancer Cytopathol 84: 109-114, 1998

    Google Scholar 

  7. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J. Cdk-interacting prote in 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase ? holoenzyme. Proc Natl Acad Sci USA 91: 8655-8659, 1994

    Google Scholar 

  8. Rochefort H, Augereau P, Capony F, Garcia M, Cavailles V, Freiss G, Morisset M, Vignon F. The 52k cathepsin-D of breast cancer; structure, regulation, function and clinical value. Cancer Treat Res 40: 207-212, 1988

    Google Scholar 

  9. Foekens JA, Rio MC, Seguin P, Van Putten WL, Fauque J, Nap M: Prediction of relapse and survival in breast cancer patients by PS2 protein status. Cancer Res 50(13): 3832-3837, 1990

    Google Scholar 

  10. Gillesby BE, Zacharewski TR: PS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 56(3): 253-265, 1999

    Google Scholar 

  11. Kato T, Kimura T, Ishii N, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T: The methodology of quantification of microvessel density and prognostic value of neovascularisation associated with long-term survival in Japanese patients with breast cancer. Breast Cancer Res Treat 53(1): 19-31, 1999

    Google Scholar 

  12. Badenoch-Jones P, Claudianos C, Ramshaw IA. Lectinbinding characteristics of related high and low metastatic rat mammary adenocarcinoma cell lines. Invasion Metastasis 7(5): 284-296, 1987

    Google Scholar 

  13. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat 56(2): 105-121, 1999

    Google Scholar 

  14. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR: Differences in Ki67 and c-erbB2 expression between screen detected and true interval breast cancers. Clin Cancer Res 5(10): 2682-2688, 1999

    Google Scholar 

  15. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, Hendrix MJ: Association between keratin and vimentin expression, malignant phenotype and survival in postmenopausal breast cancer patients. Clin Cancer Res 5(10): 2698-2703, 1999

    Google Scholar 

  16. Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46: 2889-2895, 1980

    Google Scholar 

  17. Coppola D, Catalano E, Nicosio SV. Significance of P53 and bcl-2 protein expression in human breast ductal carcinoma. Cancer Control, JMCC 6(2): 181-187, 1999

    Google Scholar 

  18. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma: P53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98(4): 408-418, 1992

    Google Scholar 

  19. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, Parwaresch R: Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 55(1): 61-71, 1999

    Google Scholar 

  20. Kawabata K, Watanabe K, Ozaki S. Expression of PS2 protein in breast cancer. Rinsho Byori 44(7): 647-652, 1996

    Google Scholar 

  21. Reshkin SJ, Tedone T, Correale M, Mangia A, Casavola V, Paradiso A. Association of PS2 (TFF1) with breast tumor proliferative rate: in vitro and in vivo studies. Cell Prolif 32(2-3) 107-118, 1999

  22. Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM. Immunohistochemical determination of PS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34(2): 119-128, 1995

    Google Scholar 

  23. Besse G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau JP, Brunelle P, Wafflart J, Angibeau RM, Auvray E. PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study. Bull Cancer 81(4): 289-296, 1994

    Google Scholar 

  24. Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB. Evaluation of predictive value of Her-2/neu overexpression and P53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 18(10): 2070-2080, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal medicine, Division of Medical Oncology, Akdeniz University Medical Faculty, Antalya, Turkey

    H. Bozcuk, G. Uslu, M. Samur & B. Savaş

  2. Department of Pathology, Akdeniz University Medical Faculty, Antalya, Turkey

    E. Peştereli, Ş Karaveli & F. Sargın

  3. Department of Internal medicine, Division of Medical Oncology, Department of Pathology, Akdeniz University Medical Faculty, Antalya, Turkey

    M. Ozdoğan

Authors
  1. H. Bozcuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Uslu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Peştereli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Samur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Ozdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ş Karaveli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Sargın
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Savaş
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bozcuk, H., Uslu, G., Peştereli, E. et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 68, 239–248 (2001). https://doi.org/10.1023/A:1012269804578

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012269804578

Search

Navigation